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A B S T R A C T
The neurotransmitter γ-amino butyric acid (GABA) has a fundamental role in CNS function and ionotropic
(GABAA) receptors that mediate many of the actions of GABA are important therapeutic targets. This study
reports the mechanism of action of novel GABAA antagonists based on a tricyclic oxazolo-2,3-benzodiazepine
scaﬀold. These compounds are orthosteric antagonists of GABA on heteropentameric GABAA receptors of
αxβ2γ2 conﬁguration expressed in HEK293 cells. In silico modelling predicted that the test compounds docked
in the GABA binding-pocket and would interact with amino-acid residues in the α- and β-subunit interface that
are known to be important for the binding of GABA. Intriguingly, optimal docking also required an interaction
with the non-conserved amino-terminal segment of Loop-F of the α–subunit. Testing of a compound with
altered regiochemistry of the oxazolone moiety supported the model with respect to the conserved GABA-
interacting residues in vitro as well as in vivo. The prediction regarding loop-F was examined by replacing the
amino-terminal variable segment of loop-F of the α5-subunit with the corresponding residues in the α1- and α2-
subunits. When tested with the novel inhibitors, the receptors formed by the modiﬁed α5-subunits displayed the
pharmacologic phenotype of the source of loop-F. In summary, these data show that the variable amino-
terminal segment of loop-F of the α-subunit determines the pharmacologic selectivity of the novel tricyclic
inhibitors of GABAA receptors.
1. Introduction
Gamma-aminobutyric acid (GABA) is a fundamentally important
neurotransmitter in the CNS (Klausberger and Somogyi, 2008; Walker,
1983). Ionotropic (GABAA) receptors for GABA constitute a subfamily
of Cys-loop, ligand-gated ion-channels (CLIG) assembled from a
repertory of 19 genes (Barnard et al., 1988; Miller and Smart, 2010;
Olsen and Sieghart, 2008; Rudolph and Möhler, 2014). Each receptor
consists of ﬁve membrane-spanning protein subunits lining a central
pore that is highly selective for Cl- (Barnard et al., 1988; Miller and
Smart, 2010; Olsen and Sieghart, 2008; Rudolph and Möhler, 2014).
The predominant subunit conﬁguration of neuronal GABAA receptors
is 2α+2β+1γ, i.e. heteropentameric. The GABA ligand-binding pocket
is formed at the interface of the extracellular domains of the α and β
subunits. Whilst all three subunits are encoded by distinct gene
subfamilies, it is thought that the bulk of functional receptor isoforms
consist of identical α and β subunits (McKernan and Whiting, 1996).
Evidence for naturally occurring “hetero-alpha” GABAAR complexes
has been also published (Araujo et al., 1999; McKernan and Whiting,
1996; Nusser et al., 1998; Pollard et al., 1995). However, the biologic
and potential pharmacologic signiﬁcance of hetero-alpha GABAARs
remains unclear.
Ionotropic GABAA receptors are the targets of several types of drugs
including barbiturates, benzodiazepines and halogenated inhalational
anaesthetics (Olsen and Sieghart, 2008; Rudolph and Möhler, 2014).
Whilst therapeutically highly important in a variety of clinical condi-
tions, the use of these drugs is complicated by prominent unwanted
side-eﬀects. Thus, considerable eﬀort has been made to develop
compounds that would selectively target GABAA receptor isoforms.
The vast majority of the selective compounds developed in the past 20
years were allosteric modulators at the benzodiazepine site (Atack,
2011a; Olsen and Sieghart, 2008; Skolnick, 2012; Wikipedia, 2015).
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However, the clinical development of all of these drugs, bar basmisanil,
has been stopped.
Previously, we reported the chemical synthesis and partial biologic
characterization of a family of tricyclic compounds based on an
oxazolo-2,3 benzodiazepine scaﬀold (Ling et al., 2015). The com-
pounds are orthosteric inhibitors of GABA binding at the β–α subunit
interface. In some cases this property is paired with inhibition of
channel opening induced by etomidate, which is similar to the proﬁle of
the GABA antagonist, bicuculline (Ueno et al., 1997). However, in
contrast to bicuculline, which is a non-selective blocker of all GABAA
receptor isoforms, some of the novel tricyclic compounds showed
considerable isoform selectivity. For instance, compound 1b (Fig. 1)
appears to be a selective blocker of extra-synaptic α5-GABAARs (Ling
et al., 2015).
The present study investigated the structural determinants of the
selectivity of the novel tricyclic GABAA inhibitors by in silicomodelling,
followed by testing of the predictions of the model by in vitro and in
vivo bioassays. The results conﬁrm previous ﬁndings (Ling et al., 2015)
that the novel tricyclic antagonists dock in the GABA-binding pocket.
Importantly, and in contrast to GABA agonists, the docking of the
compounds at the GABA-site appears to require an interaction with the
NH2-terminal variable portion of loop-F of the α–subunit thus achiev-
ing a signiﬁcant degree of isoform selectivity.
2. Materials and methods
2.1. Compounds
All experimental compounds (Fig. 1) were synthesized at Egis
Pharmaceuticals PLC as previously described (Ling et al., 2015), and
were used at 95% purity or greater. All chemical and biochemical
reagents were of the highest grade available. For all in vitro experi-
ments a stock solution of the drug (10 mM) was dissolved in 100%
DMSO aliquoted and stored at −20 °C. In the in vitro assays 0.1%
DMSO had no eﬀect on the various control recordings made. For in
vivo administration, drugs were dissolved in DMSO and diluted further
in 0.4%(w/v) hydroxypropyl methylcellulose suspension (Methocell F4
M, Dow Chemical Company, USA) on the day of testing to achieve a
ﬁnal concentration of DMSO of 1% (v/v).
2.2. Cell culture
Stable human embryonic kidney cell (HEK293) lines obtained upon
transfection with cDNAs encoding human α-subunit isoforms as well as
with cDNA for rat β2 (short) and rat γ2 (long) in antibiotic resistance
variants of the expression vector pcDNA3.1 (Life Technologies, Inc.,
Carlsbad, CA, USA) or pExchange (Agilent Technologies, Inc., Santa
Clara, CA, USA) have been described (Ling et al., 2015). The GABAA
αxβ2γ2 cell lines were maintained under triple antibiotic selection using
neomycin (0.6 mg/ml), zeocin (0.2 mg/ml) and puromycin (3 µg/ml)
in Dulbecco's MEM supplemented with 10 v/v% fetal bovine serum and
10 mM KCl. A further cell line, co-expressing GABAA β2- and γ2-
subunits was propagated under selection with neomycin (0.6 mg/ml),
zeocin (0.2 mg/ml), in Dulbecco's MEM supplemented with 10 v/v%
fetal bovine serum. These cells were transiently transfected by the
calcium-phosphate method (Salmon and Trono, 2006) with the ex-
pression vectors of the requisite wild-type and variously mutated α-
subunit cDNAs. The cells were collected 48 h later, frozen in a mixture
of fetal bovine serum and 10% (v/v) DMSO in aliquots suﬃcient for
seeding a 96-well plate and stored at −150 °C until further use.
2.3. Site-directed mutagenesis
Mutations were introduced by site-directed mutagenesis with
custom-designed primers using Phusion High-Fidelity DNA
Polymerase (Thermo Fisher Scientiﬁc Waltham, MA USA) as per the
manufacturer's instructions. The resulting constructs were veriﬁed by
DNA sequencing of the entire coding region (Biomi Ltd, Gödöllő,
Hungary).
2.4. FLIPR dye assay
For ﬂuorescence recordings cells were plated in black, clear-bottom,
half-volume 96-well plates coated with poly-D-lysine at 50,000 or
100,000 cells per well for stable cell lines and transiently transfected
cells, respectively, in 50 µL of growth medium and used 24 h later
exactly as reported previously (Ling et al., 2015). Brieﬂy, the cells were
washed and incubated at 37 °C in 20 mM HEPES buﬀered Hank's
Balanced Salt Solution (HBSS), pH 7.4 supplemented with FLIPR
Membrane Potential Assay Kit BLUE (Molecular Devices, Biberach an
der Riß, Germany) dye at 2× dilution. Simultaneously with dye-loading
various concentrations of the test compound dissolved in HBSS
Fig. 1. The test compounds used in this study.
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supplemented with 20 mM HEPES, pH 7.4 and 1% (v/v) DMSO were
added to the incubation medium at 37 °C. The ﬁnal concentration of
DMSO in the medium was 0.1% (v/v). Forty min later the plates were
placed into a Flexstation3 (Molecular Devices) plate reader and the
recording of ﬂuorescence was started — designated as time 0.
Subsequently, the ﬂuorescence signal was sampled at 2 s intervals,
the stimulus (GABA or etomidate) was introduced at 30 s, the record-
ing was terminated at 120 s after time 0. Note, that because of the high
intracellular concentration of Cl-, the opening of Cl- channels in these
cells induces depolarization of the membrane potential (Thomas and
Smart, 2005) i.e. an increase of the ﬂuorescence signal monitored in
this study (Ling et al., 2015). The area under the curve of time vs.
relative ﬂuorescence units after the addition of GABA was calculated
with the average baseline subtracted by Soft-Max 5.4 software
(Molecular Devices) and used for further analysis. Non-linear regres-
sion curves were ﬁtted using GraphPad Prism version 6.0 and the IC50
values to inhibit the eﬀect of GABA were read from the curve. In order
to make data comparable between experiments, the results are
expressed as percentage of the response evoked by GABA at EC20-
EC50 depending on the type of the experiment, as speciﬁed in the ﬁgure
legends.
2.5. Homology modelling
The protocol described by Sander and co-workers (Sander et al.,
2011) was followed (see Supplement for further details). However, we
used the X-ray structure of a ligand C. elegans glutamate-gated
chloride channel (Hibbs and Gouaux, 2011) as a template. This
ligand-bound receptor structure is an invaluable asset for the homology
modelling of GABAA receptors, as none of the templates used pre-
viously was a member of this receptor family. The details of the model
building, reﬁnement and validation are described in the Supplement.
For the sake of comparability we follow the consensus of the corre-
sponding literature in the residue numbering of the subunits. It starts
as 9-DNTTV, 7-SNMSL and 22-VPEGD for the subunits α1, β2 and γ2,
respectively.
2.6. Novel object preference in mice
Male NMRI mice bred in house were used at 20–30 g body weight.
The animals were housed four/cage under standard laboratory condi-
tions (24 ± 2 °C, 40–60% relative humidity), on a 12-h light/dark cycle
with light onset at 6:00 AM (Initial Zeitgeber 3). All experimental
protocols were approved by the Animal Care and Use Ethical
Committee of Egis Pharmaceuticals PLC and complied with the
Hungarian Law of Animal Care and Use (1998. XVIII). The test was
carried out as previously reported for rats (Gacsályi et al., 2013) with
minor modiﬁcations. On day 0 (familiarization), the test animals were
put in the empty test box (without objects) one by one for 2.5 min each
(test box: 24×34×24 cm, black, Plexiglas). The acquisition trial started
on day 1 (i.e. 24 h after the end of familiarization; during this time-
interval the animals were deprived of food (1 pellet /4 mice) until the
end of the acquisition trial). On day 1 (acquisition), each animal was
placed in the middle of the test box 60 min after treatment with drug or
vehicle. During this trial, mice were allowed to explore two identical
objects for 10 s per object (within a cut-oﬀ time of 5 min). Exploration
time was measured manually by stopwatch. After the 5-min acquisition
trial, each test animal was returned to its home cage with access to food
and water ad libitum. The retention trial (on day 2) was started 24 h
after the acquisition trial by placing the test animal in the test box
containing a replica of the previously explored object and a new object.
Exploration times for the two objects were measured during the 4 min
retention testing trial. Exclusion criteria: On day 1: exploration time 0 s
or extremely low interest ( < 1 s) at one object or both objects for the
duration of 5 min or the diﬀerence of duration of exploration of two
objects is > 8 s. On day 2: exploration time 0 s or extremely low
interest ( < 1 s) at one object or both objects duration of 4 min.
Treatment with test compound(s) was by i.p. injection (volume
10 ml/kg) 60 min before the acquisition trial.
3. Results
3.1. Strict requirement for interaction at the GABA binding-site for
an inhibitory eﬀect
It was previously demonstrated that 1a had no appreciable eﬀect on
etomidate-induced activation of α5β2γ2 GABAA Cl
- channels, while 2
was a strong inhibitor (Ling et al., 2015). The data in Fig. 2 show that
the inhibitory eﬀect of 2 on depolarization evoked by etomidate was
blocked by the prior application of 1a. Thus similar to bicuculline
(Thompson et al., 1999) the eﬀects of 2 are dependent on interaction
with the GABA binding-site. Taken together, these ﬁndings indicated
that binding to the GABA site(s) of the receptor is necessary for an
eﬀect on channel gating.
3.2. In silico modelling points to Loop-F as an anchoring point for
tricyclic inhibitors
Previously, we reported that the compounds displace 3H-muscimol
from the GABA site of α5-GABAA receptors, whilst having no eﬀect on
the binding of the benzodiazepine-site ligand 3H-ﬂumazenil (Ling
et al., 2015). In an attempt to understand the mode of interaction of
the drugs with the GABA site, in silicomodelling was used. A homology
model of the α1β2γ2 GABAAR was constructed based on the CLIG
homopentameric C. elegans glutamate-gated chloride channel (Hibbs
and Gouaux, 2011). This particular GABAAR conﬁguration was chosen
because of the wealth of functional of data available on its physiology
and pharmacology thus allowing validation of our modell (Krall et al.,
2015; Puthenkalam et al., 2016; Sander et al., 2011). Ligand 2 was
docked to the reﬁned GABA binding site using the induced-ﬁt docking
protocol of the Schrödinger Program Suite (IFD-Schrödinger LLC).
Based on the interaction patterns of the 5-(4-piperidyl)-3-isoxazolol
and 4-(piperidin-4-yl)-1-hydroxypyrazole derived ligands used by
Sander et al. (Sander et al., 2011), we selected the binding pose where
Arg66 and Arg119 of the α1-subunit interacted with the oxazolone
moiety of the ligand. Loop F of the α1-subunit was reﬁned using the
Prime program (Prime-Schrödinger LLC). The binding position of 2,
together with the schematic map of its interactions, is shown in Fig. 3.
Fig. 2. Inhibition of etomidate-induced depolarization by 2 is blocked by 1a. HEK293
cells stably expressing α5β2γ2 GABAARs, data are means, bars represent S.E.M. n=3.
Etomidate concentration was 60 µM (≈EC40), the cells were pretreated for 40 min prior
to the introduction of etomidate with various concentrations of 2 (circles) or 2 and 1a
(10 µM, triangles). Representative study from two independent experiments.
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As outlined above, the lactone oxygens of the oxazolone moiety were
predicted to interact with Arg66 and Arg119, which are known
interactors of GABA. Moreover, there was signiﬁcant proximity of the
top of the tricyclic ring with the sequence REPAR mainly in the case of
Glu173 and Pro174 of the amino-terminal portion of loop-F of the α1-
subunit. The benzothiophene moiety of 2 is found in a hydrophobic
pocket formed mainly by Tyr97, Tyr157 and Tyr205 and Phe45, Phe64,
Phe200 from the β2- and α1-subunit, respectively. The benzene ring of
benzothiophene is situated near Glu155 of the beta subunit, which is a
residue also known to be relevant for the interaction with GABA
(Newell et al., 2004). The isoquinoline rings were predicted to be
surrounded by the hydrophobic residues Ile44, Phe45, Phe65 and
Val178 of the α1-subunit, the latter is also part of loop F. Thus, the
docking studies led to the testing of two hypotheses. First, that the
orientation of the oxazolone moiety is critical for binding to the GABA
site, and second, that the variable NH2-terminal segment of loop-F of
the alpha subunit is also involved.
3.3. Regiochemistry of the oxazolone moiety in vitro and in vivo
Compounds 1c-1 and 1c-2 (Fig. 1) are regiochemical isomers with
respect to the positions of N and O in the oxazolone ring. The in silico
prediction was that the 1c-1 regiochemistry is an absolute requirement
for docking in the GABA binding pocket. Indeed, as shown in Fig. 4, 1c-
1 produced robust inhibition of the GABA response mediated by
recombinantly expressed α5β2γ2 GABAARs whereas 1c-2 was ineﬀec-
tive up to 100 µM. These results could be also corroborated in vivo.
Experimental manipulation of α5-GABAAR function is known inﬂuence
cognitive performance in rodents (Atack, 2011b; Rudolph and Möhler,
2014). The novel object preference test (Clark, 2013; Kinnavane et al.,
2015) in mice, is exquisitely sensitive to compounds inﬂuencing α5-
GABAARs (Ling et al., 2015; Milic et al., 2013; Redrobe et al., 2012). In
concordance with the ﬁndings on recombinant receptors, compound
1c-1 showed the behavioural eﬀect expected of an inhibitor of α5-
GABAARs: it signiﬁcantly improved the exploration of the novel object
at 10 mg/kg, i.p.. In contrast, compound 1c-2 was without signiﬁcant
eﬀect, in agreement with its lack of α5-GABAAR antagonist eﬃcacy in
vitro (Fig. 5).
3.4. Role for loop-F of the α-subunits in the inhibitory action of novel
tricyclic α5-GABAA antagonists
Alignment of the primary sequences of the GABAA α-subunits
reveals signiﬁcant non-homology of the NH2- terminal portion of
loop-F between the subunit paralogs (Supplementary Fig. 5).
Moreover, most of the novel tricyclic inhibitors tested showed a close
to 100-fold selectivity for α5-GABAARs over α2-GABAARs (Ling et al.,
2015). Thus, α5 “microchimeras” were prepared with sequence mod-
iﬁcations derived from the NH2-terminal segment of loop-F of the α2-
(α5-LFα2) and α1-subunits (α5_LFα1), respectively (Fig. 6 and
Supplement Fig. 5). Testing of 1b and 2 on α5-LFα2 subunits revealed
a marked reduction of inhibitory potency which was quantiﬁable for
compound 2: a reduction of 55-fold to 1.6 µM (Fig. 7). In the case of
1b the lack of a full inhibition of the GABA-induced response on α5-
LFα2-GABAARs precluded a valid comparison (Fig. 7.). In contrast,
only a relatively modest right-shift was found for compound 1a. By
comparison, 2 had an IC50 of 993 nM (geometric mean 95% conﬁdence
interval=795–1240, n=4) on wild-type α2β2γ2 receptors, while there
was no readily quantiﬁable eﬀect of 1a or 1b at up to 10 µM. In the
case of 2, alanine scan of the core loop-F sequence NGSTK revealed
that with the exception of asparagine the mutation of all positions to
alanine caused a statistically signiﬁcant diminution of the IC50 of 2
(Fig. 8.). The greatest eﬀect was produced by R176A, which caused a
close to ten-fold reduction in potency. However, none of the point
Fig. 3. In silico modelling of the interaction of compound 2 with the GABA binding pocket formed at the interface of the α1 and β2 subunits A) The binding position of 2 in the GABA
binding pocket of the α1β2γ2 type GABAAR in close proximity to residues 172–176 (REPAR) from loop F of the α1 subunit, Legend: α1 and β2 subunits are presented in ribbon
representation coloured orange and yellow, respectively. Ligand 2 appears in stick and ball representation with green carbon atoms. The bonds of residues 172–176 (REPAR) of subunit
α1 are presented as tubes with grey carbon atoms, the corresponding part of the main chain is red. B) Interaction map of ligand 2. H-bonds are represented by magenta arrows, π-π
stacking interactions appear as green lines.
Fig. 4. Strict requirement for the regiochemistry of the oxazolone ring in vitro. HEK293
cells stably expressing α5β2γ2 GABAARs stimulated with 1.6 µM GABA (≈EC40), data are
mean ± S.E.M. n=3/group. Cells were pre-treated for 40 min prior to the introduction of
GABA with various concentrations of 1c-2 (circles) or 1c-1 (triangles). Representative
study from two independent experiments.
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mutations approached the reduction in potency seen with the α5-LFα2
construct.
With respect to receptors containing the α5_LFα1 subunit, inhibi-
tion by 1b appeared to fully recapitulate the features of its action on
wild-type α1β2γ2 GABAARs (Fig. 9). When given alone, 1b had no
eﬀect on the ﬂuorescence signal at concentrations up to 3 µM. In
contrast, the characteristics of 2 to inhibit α5_LFα1 receptors were not
diﬀerent from that on α5 receptors (data not shown).
4. Discussion
The results of the present study conﬁrm and extend the ﬁnding that
the novel tricyclic GABAA inhibitors have pharmacologic properties
similar to bicuculline (Ling et al., 2015; Thompson et al., 1999; Ueno
et al., 1997). Interaction of the drugs with the GABA binding-pocket of
the GABAA receptor is essential for biologic eﬃcacy, which has two
components. First, competitive inhibition of GABA and second, inhibi-
tion of Cl--channel gating, which becomes apparent when etomidate, a
positive allosteric mediator with respect to GABA, is the stimulus.
However, some of the compounds (e.g. 1a) show no discernible eﬀect
on channel gating. Importantly, considerable GABAA α-subunit selec-
tivity (Ling et al., 2015) is evident for oxazolo-2,3,benzodiazepines
such as 1b, which is potentially exploitable for clinical therapy.
The α1β2γ2 GABAAR homology model reported in the present
study was largely compiled according to the procedure of Sandberg
et al. (Sander et al., 2011) and gave satisfactory docking results for the
same set of GABA analogs as tested by these workers. With respect to
the docking of the novel tricyclic inhibitors in the GABA binding
pocket, the in silico modell provided two signiﬁcant and testable
hypotheses. The ﬁrst concerned the orientation of the oxazolone moiety
in the binding pocket (Fig. 4b.). The required regiochemistry with
respect to the position of O and N in the oxazolone ring was
experimentally validated in vitro as well as in vivo, thus supporting
the notion regarding the orientation of the compounds in the L-shaped
Fig. 5. Strict requirement for the regiochemistry of the oxazolone ring in vivo. Object recognition assay in NMRI mice after treatment with vehicle or 1, 3 and 10 mg/kg, i.p. of 1c-1
(left) or 1c-2 (right). Data are mean ± S.E.M. n=10/group. The animals were allowed 10 s per object contact time (within a cut-oﬀ time of 5 min) in the acquisition phase. The test trial
took place 24 h later and lasted 4 min. N=time spent in contact with novel object, F=time spent in contact with the familiar object. Animals were injected i.p. with vehicle or the indicated
dose of the compounds 60 min prior to the acquisition trial.
Fig. 6. A. Schematic representation of the extracellular N-terminal domain of a GABAA receptor subunit with the relative positions of the beta-sheets (numbered) indicated (Ernst et al.,
2005). Ribbons indicate beta-sheets, the arrowheads point towards the carboxyl-terminus. Lines show the connecting loops, Loop-F is highlighted in blue. TM – beginning of the ﬁrst
transmembrane domain. B. The mutations introduced into loop-F of the GABAA α5-subunit – derived from homologous sections of the α1 and α2 subunits, respectively (Also see
Supplementary Fig. 5).
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binding pocket.
Second, given the orientation of the oxazolone moiety, the model
indicated that the GABAAR isoform selectivity of the test compounds
could be derived from interactions with the variable NH2-terminal
segment of the loop-F of the α-subunit. Loop-F (called loop 9 in some
studies) connects beta-sheets 8 and 9 of the extracellular domain of
GABAARs (Fig. 7A). Loop-F has no known structure (Bergmann et al.,
2013; Miller and Aricescu, 2014) and its functional role in GABAAR is
not fully understood (Khatri and Weiss, 2010; Lynagh and Pless,
2014). High-resolution structural analyses (Miller and Aricescu, 2014;
Spurny et al., 2012) indicated that while loop-F is in close proximity of
the GABA binding-pocket, it is not part of it. In contrast, homology-
based computer modelling indicated that the lower, carboxyl-terminal
domain of loop-F, including Val178 and Val180, faces the GABA
binding-pocket (Bergmann et al., 2013; Newell and Czajkowski,
2003; Puthenkalam et al., 2016; Sander et al., 2011). Moreover, N-
Biotinylaminoethyl methanethiosulfonate labelling implicated R176,
Val178 and Val180 in the action of GABA (Newell and Czajkowski,
2003). However, point mutations to cysteine in loop-F the α-subunit of
α1-GABAAR had no signiﬁcant eﬀect on GABA potency (Newell and
Czajkowski, 2003). It is well documented that loop-F undergoes
marked conformation changes upon the binding of GABA in GABA-C
receptors (Khatri et al., 2009; Zhang et al., 2009). Similar ﬁndings were
reported upon proton activation of the prokaryotic channel GLIC
(Dellisanti et al., 2013). Analysis of molecular dynamic simulations of
a homology model of heteropentameric receptors with GABA α1 or α6
subunits indicated that loop-F regulates the aﬃnity for GABA in a
subunit-speciﬁc manner (Carpenter et al., 2012). Taken together, in
GABAARs the role of loop-F of the α-subunit is controversial with
respect to the binding and recognition of agonists. More pertinent for
the present study are the reports showing that the potency of the
competitive antagonists d-tubocurarine and strychnine on the CLIG-
family member 5-HT3, nicotinic as well as glycine receptors is strongly
dependent on the sequence of loop-F (Dutzler et al., 2011; Zhang et al.,
2007). However, in contrast to GABAARs, it is well established that
loop-F contributes to the agonist binding-pocket of these receptors
(Lynagh and Pless, 2014).
The present study found that the three novel analogs tested on
recombinantly expressed α5_LFα2β2γ2 GABAARs displayed diﬀerent
changes in potency. Compounds 2 and 1b had characteristics closely
resembling those on recombinantly expressed wild-type α2β2γ2
GABAARs. By contrast, in the case of compound 1a only a minor
right-shift of the concentration-response curve was observed, whereas
this compound was without quantiﬁable eﬀect on wild type α2β2γ2
GABAARs. With respect to α5_LFα1β2γ2 GABAARs, the pattern of
inhibition by compound 1b closely resembled that seen in α1β2γ2
GABAARs. In contrast, the potency and maximal eﬀect of 2 remained
unaltered, i.e. retaining roughly 10-fold selectivity towards α5β2γ2
GABAARs over α1β2γ2 GABAARs (Ling et al., 2015). These data
indicate that the contribution of loop-F to the potencies of the test
compounds may vary with the compound tested as well as with the α-
subunit investigated. Thus these compounds may prove useful to
explore the various conformations of loop-F of the α-subunits.
Intriguingly, 1b, a compound with drug-like properties that appeared
to be selective for extrasynaptic α5-GABAARs (Ling et al., 2015),
showed the most marked and consistent loop-F dependence.
Alanine-scan of the NGSTK sequence in α5-GABAARs indicated
contributions of all residues apart from N173 to the potency of 2, with
residue K176 causing the largest right-shift of about 10-fold. By
comparison, the potency of 2 on receptors containing microchimeric
α5_LF2 subunits was reduced by over 50-fold. Taken together, the
results indicate that it is the ensemble of loop-F stretching from
residues 169 to 182 that is required for the high-aﬃnity binding of
the test compounds to the GABA binding-pocket. Given the structural
ﬂexibility of loop-F and the localized sequence variability at positions
173–177, a wide spectrum of receptor-drug conformers is likely to
contribute to the macroscopic characteristics of the cellular response to
Fig. 7. Eﬀects of introducing mutations derived from the GABAA α2-subunit into loop-F of the GABAA α5 subunit on the potencies of compounds 2, 1a and 1b to inhibit the
depolarization evoked by 0.4 µM GABA (≈EC60 for both receptors). HEK293 cells stably expressing β2γ2 subunits and transiently transfected with α5 (circles) or α5_LFα2 (triangles)
subunit cDNA. Data are mean ± S.E.M. n=3/group. Representative study from two independent experiments.
Fig. 8. Alanine-scan of loop-F with respect to the inhibitory action of compound 2 on
α5β2γ2 GABAAR transiently expressed in HEK293 cells. In each case the pIC50 value was
determined against 0.8 µM GABA ≈EC20–50 as the stimulus, the pIC50 value was
calculated by non-linear regression using Graph-Pad Prism four-parameter curve-ﬁtting.
The results of individual experiments are shown, horizontal bars represent the mean.
Wild type (WT), single letter amino acid code is used on the x-axis to indicate which
amino acid was mutated to A. One-way ANOVA, followed by Dunnett's test for multiple
comparisons, * P < 0.05, ** P < 0.01 when compared to from WT.
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the novel tricyclic GABAA antagonist compounds.
5. Conclusion
The data presented here conform to the hypothesis that the novel
tricyclic α5-GABAA antagonist compounds bind to the GABA site(s) of
GABAA hetero-pentameric receptors. Binding of the compounds at the
GABA-site is dependent on an interaction with the NH2-terminal
segment of loop-F of the alpha subunit. As this part of the protein
shows marked sequence variability between the alpha subunit paralogs,
the interaction with loop-F imparts a signiﬁcant degree of GABAA
receptor subtype selectivity to the novel antagonists. A member of this
class of compounds is now in Phase 2 clinical trials (https://www.
clinicaltrialsregister.eu/ctr-search/trial/2016-001005-16/HU).
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